{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"288"}],"units":"Participants"}],"title":"Pre-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"287"}],"units":"Participants"}],"title":"On-treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"156"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"275"},{"groupId":"OG001","value":"275"}],"units":"Participants"}],"title":"Post-treatment survival follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"168"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"288"}],"units":"Participants"}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"284"},{"groupId":"OG001","value":"288"}],"units":"Participants"}],"description":"Pre-treatment deaths were collected from randomization to the day before first dose of study medication.\n\nOn-treatment deaths were collected from start of treatment to 30 days after last dose of study medication.\n\nPost-treatment survival follow-up deaths were collected from day 31 after last dose of study treatment to end of study.","groups":[{"description":"Subjects with advanced breast cancer with or without a PIK3CA mutation treated with alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)","id":"OG000","title":"Alpelisib + Fulvestrant"},{"description":"Subjects with advanced breast cancer with or without a PIK3CA mutation treated with placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)","id":"OG001","title":"Placebo + Fulvestrant"}],"paramType":"NUMBER","populationDescription":"All subjects who were randomized to study treatment.","reportingStatus":"POSTED","timeFrame":"Pre-treatment: Up to 35 days. On-treatment: Up to approx. 6.5 years. Post-treatment survival follow-up: Up to approx. 6.5 years","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}